DNA Vaccines Generate Excitement As Human Trials Begin

'ABSOLUTELY AMAZING': Yerkes' Harriet Robinson notes that research in the field has grown at an extraordinarily rapid rate. With more pathogens developing resistance to antibiotics, and with the increasing vulnerability of human populations to infectious diseases, vaccine research has taken on a new urgency. Among the technologies being developed for the vaccines of the 21st century is the novel idea of using naked DNA-a simple loop of DNA containing an antigen gene-to induce an immune respons

Written byRobert Finn
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share


'ABSOLUTELY AMAZING': Yerkes' Harriet Robinson notes that research in the field has grown at an extraordinarily rapid rate.
With more pathogens developing resistance to antibiotics, and with the increasing vulnerability of human populations to infectious diseases, vaccine research has taken on a new urgency. Among the technologies being developed for the vaccines of the 21st century is the novel idea of using naked DNA-a simple loop of DNA containing an antigen gene-to induce an immune response (K.S. Brown, The Scientist, 10[7]:14, April 1, 1996).

These DNA vaccines (some researchers prefer other terms, including "genetic vaccines") offer the hope of vaccines that may be simple to develop, safe and highly effective, and easy to transport and store. Preclinical research on DNA vaccines has been highly promising, according to a 1997 report published by the American Academy of Microbiology (available on the Web at http://www.asmusa.org/acasrc/aca1.htm). And this seems to be one of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies